MétaCan
Menu
← Back to cohort

Challenges in heart failure ESC Guidelines implementation - insights from a real world registry

2025· article· en· W7127571100 on OpenAlexaff
M G De Angelis, L Assoni, M Amarante, Antonio Maria Sammartino, Miguel Ángel Mazzini, Elisa Brangi, Savina Nodari

Bibliographic record

VenueEuropean Heart Journal · 2025
Typearticle
Languageen
FieldMedicine
TopicHeart Failure Treatment and Management
Canadian institutionsSurgical Specialties (Canada)
Fundersnot available
KeywordsHeart failureEjection fractionObservational studyAmbulatoryPopulationRetrospective cohort studyMEDLINE

Abstract

fetched live from OpenAlex

Abstract Background ARNIs and, more recently, SGLT2i inhibitors have become part of the cornerstone of the treatment of heart failure garnering in the latest HF guidelines a Class I recommendation for patients with heart failure and reduced ejection fraction (≤40%). Alongside with renin-angiotensin-aldosterone system inhibitors and beta-blockers, they are recognized as "disease-modifying" drugs which should be promptly initiated in HF patients. Despite the evident benefits demonstrated by these drugs, their utilization in clinical practice remains limited. Purpose The aim of this study was to evaluate the implementation and the uptitration of heart failure "disease-modifying" drugs in the real world, as well as the eligibility rate of the study population for these treatments. Methods Our data derive from an observational study enrolling 165 consecutive ambulatory patients with heart failure regardless of ejection fraction. The study comprises several phases: 1) a T0 phase involving a retrospective analysis of several anamnestic, clinical, laboratory and echocardiographic parameters collected within one to seven months before study initiation; 2) a T1 phase prospectively evaluating the same patient characteristics over a period extending from the fifth to the seventh month following specific educational initiatives regarding HF-GMDT implementation. Results 165 consecutive patients were enrolled in our center during phase T0:90% of them were in treatment with a beta-blocker; 73% were receiving an ARNI/ACEi/ARB and 62% an MRA with main causes of underprescription in HFrEF patients being kidney dysfunction, hyperkalaemia, hypotension and bradycardia; 85% of our HFrEF patients were in treatment with SGLT2i and recurrent urinary tract infections and kidney dysfunction were the main reasons for underprescription. Only a small portion of our patients wasn't receiving disease modifying therapies because of unknown reasons (0,04% - 0,2% and 0,05% respectively for ACE/ARNI/ARB - MRA and BB). Nevertheless target doses were attained in a minority of the patients (29% -10% and 36% respectively for ARNI - MRA and BB). Conclusion While a satisfactory proportion of our patients were on heart failure medications, the majority of them did not attain target dosages, suggesting a potential gap between guideline recommendations and clinical practice. The prospective phase of our study (T1) holds the promise of assessing whether the implementation of specific educational initiatives might contribute to heightened awareness regarding the efficacy and safety of these "disease modifiers" therapies, thus facilitating their integration into clinical practice.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.032
metaresearch head score (Gemma)0.077
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.032
Threshold uncertainty score0.168

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0320.077
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0020.005
Science and technology studies0.0010.001
Scholarly communication0.0040.003
Open science0.0010.002
Research integrity0.0020.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.111
GPT teacher head0.386
Teacher spread0.276 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Heart Journal→Same topicHeart Failure Treatment and Management→French-language works237,207→